▶주메뉴 바로가기
▶본문 바로가기
Daewoong Pharmaceutical said Monday that cumulative sales of its proprietary botulinum toxin product Nabota surpassed 1 trillion won ($665 million) as of June 30, marking the milestone 12 years after its domestic launch. Nabota recorded an average annual sales growth rate of 57 percent between 2019 and 2025. Annual sales exceeded 200 billion won in 2025, driving cumulative sales past the 1 trillion won mark. The botulinum toxin has expanded its global footprint after securing approvals from the
Korea's space industry, which has been dominated by rockets and satellites up until now, is gearing up to welcome a relatively new type of partner — drugmakers. As microgravity in space allows proteins to grow into larger and more uniform crystals, it helps scientists better understand the three-dimensional structures of disease-related proteins. This helps drug discovery by giving an accurate picture of what shape drug molecules have to be in order to function. Microgravity can accelerate biolo
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration issued a Complete Response Letter delaying approval, citing manufacturing compliance issues rather than concerns over the drug's clinical data. HLB said Friday that its US subsidiary, Elevar Therapeutics, received the CRL from the FDA regarding its new drug application for Rivoceranib, an anti-cancer therapy intended for use in the treatment of liver cancer. Ac
CHUNCHEON, Gangwon Province – A tube thinner and shorter than a thumb, holding what looks like little more than a drop or two of clear liquid, sat locked inside an ultralow-temperature freezer at minus 80 degrees Celsius in Building A of Hugel’s Geodu factory in Chuncheon, Gangwon Province, on Thursday. “That tiny tube is enough to produce more than 25,000 vials of botulinum toxin,” said Seol Hee-soo, managing director at Hugel. That little tube was among the most tightly guarded assets inside H
ABL Bio is seeking to transform itself from a licensing-focused biotech company into a globally competitive drug developer while advancing both its oncology pipeline and proprietary platform technologies. “The dream is no longer signing another large licensing agreement,” Lee Sang-hoon, CEO of ABL Bio, said at a press conference at the Conrad Seoul on Thursday. "The goal is building a company that can stand shoulder to shoulder with global pharmaceutical companies." The vision comes as ABL Bio e
Matica Biotechnology, the US contract development and manufacturing organization subsidiary of CHA Biotech, has partnered with Texas-based VaxDome Inc. to jointly develop an antigen-agnostic antiviral vaccine aimed at protecting against a broad range of infectious diseases. The collaboration will focus on advancing VaxDome's hybrid antiviral vaccine candidates into clinical trials. Under the agreement, Matica Biotechnology will provide process development, analytical development and the producti
Korean pharmaceutical company Yuhan has reaffirmed its commitment to becoming an innovative global drugmaker as it recently celebrated its centennial. “The way Yuhan has been able to walk the past 100 years was based on the two unwavering values of progress, the drive to continuously forge new ways, and integrity, the commitment to uphold principles and elevate dignity,” said Cho Wook-je, CEO of Yuhan, during the celebration of the firm’s century-long history at the Willow House, the company’s r
Celltrion said Friday it posted record second-quarter sales and a 77.3 percent jump in operating profit, as newer, higher-margin products helped lift margins and push earnings above its own guidance. The Korean biopharmaceutical company reported preliminary consolidated revenue of 1.3 trillion won ($845 million) and operating profit of 430 billion won for the April-June period. Revenue rose 35.2 percent from a year earlier, marking Celltrion’s highest-ever second-quarter sales, while operating p
Daewoong Pharmaceutical said Thursday it has signed a 145.2 billion won ($93.4 million) export and supply agreement with Switzerland-based Acino Pharma AG to launch its diabetes drug Envlo in eight major markets across the Middle East and North Africa. The company said the deal is Envlo's largest export agreement to date and marks the first entry of a Korean-developed sodium-glucose cotransporter-2 (SGLT-2) inhibitor into the MENA market. Under the agreement, Daewoong plans to secure marketing a
SK Bioscience said Thursday it will lead a Gates Foundation-funded project to develop an AI-powered platform designed to support clinical development decisions in vaccine research. The project, called Research Optimization & Trial Outcome Recommender, or ROTOR, will bring together a global consortium that includes a technical collaboration with global health nonprofit PATH and technology consulting firm Slalom. ROTOR is designed to analyze clinical, immunogenicity and scientific datasets generat
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
July 13, 2026
July 12, 2026
July 10, 2026
July 8, 2026
July 7, 2026
July 7, 2026
July 5, 2026
July 3, 2026
July 2, 2026
July 2, 2026
